泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301230 泓博医药

已收盘 08-27 15:00:00

{"stockData":{"symbol":"301230","market":"SZ","secType":"STK","nameCN":"泓博医药","latestPrice":32.79,"timestamp":1787814219000,"preClose":32.8,"halted":0,"volume":11068223,"delay":0,"changeRate":-0.0003,"floatShares":163000000,"shares":181000000,"eps":0.2548,"marketStatus":"已收盘","change":-0.01,"latestTime":"08-27 15:00:00","open":32.65,"high":33.15,"low":32.29,"amount":361000000,"amplitude":0.0262,"askPrice":32.8,"askSize":18,"bidPrice":32.79,"bidSize":171,"shortable":0,"etf":0,"ttmEps":0.2548,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787880600000},"marketStatusCode":5,"adr":0,"adjPreClose":32.8,"symbolType":"stock","openAndCloseTimeList":[[1787794200000,1787801400000],[1787806800000,1787814000000]],"highLimit":36.08,"lowLimit":29.52,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":180941126,"isCdr":false,"pbRate":5.76,"roa":"--","peRate":128.689168,"roe":"2.34%","epsLYR":0.25,"committee":0.678399,"marketValue":5933000000,"turnoverRate":0.068,"status":1,"floatMarketCap":5337000000},"requestUrl":"/m/hq/s/301230","defaultTab":"news","newsList":[{"id":"2661224824","title":"8月24日泓博医药跌5.26%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2661224824","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661224824?lang=zh_cn&edition=full","pubTime":"2026-08-24 16:42","pubTimestamp":1787560924,"startTime":"0","endTime":"0","summary":"证券之星消息，8月24日泓博医药跌5.26%，收盘报33.84元，换手率9.25%，成交量15.05万手，成交额5.15亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400022153.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449629","title":"8月19日泓博医药跌7.47%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449629","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660449629?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:15","pubTimestamp":1787130944,"startTime":"0","endTime":"0","summary":"证券之星消息，8月19日泓博医药跌7.47%，收盘报34.2元，换手率10.13%，成交量16.49万手，成交额5.79亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900029666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658799368","title":"泓博医药：截至2026年8月10日股东户数为29,532户","url":"https://stock-news.laohu8.com/highlight/detail?id=2658799368","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658799368?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:27","pubTimestamp":1786436827,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)08月11日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好！请问截止2026年8月 10日公司的股东人数是多少？谢谢！泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年8月10日（交易日），公司的股东户数为29,532户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100025686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658998550","title":"泓博医药：不存在应披露未披露的重大事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2658998550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658998550?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:45","pubTimestamp":1786434315,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药08月11日在投资者关系平台上答复投资者关心的问题。特别是在DiOrion平台商业化、热门赛道订单转化、海外大药企合作等方面？公司目前生产经营一切正常，有序开展，不存在应披露未披露的重大事项。DiOrion平台及各业务进展情况请您留意公司即将披露的定期报告。二级市场股价受多重复杂因素共同影响，存在一定波动性，敬请广大投资者注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100021022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658501981","title":"8月10日泓博医药涨8.27%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2658501981","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658501981?lang=zh_cn&edition=full","pubTime":"2026-08-10 16:49","pubTimestamp":1786351789,"startTime":"0","endTime":"0","summary":"证券之星消息，8月10日泓博医药涨8.27%，收盘报35.1元，换手率23.6%，成交量38.4万手，成交额13.56亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000021023.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616148","title":"8月7日泓博医药涨19.99%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616148","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616148?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:50","pubTimestamp":1786092645,"startTime":"0","endTime":"0","summary":"证券之星消息，8月7日泓博医药涨19.99%，收盘报32.42元，换手率15.65%，成交量25.47万手，成交额7.58亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657697557","title":"异动快报：泓博医药（301230）8月7日14点35分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2657697557","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657697557?lang=zh_cn&edition=full","pubTime":"2026-08-07 14:45","pubTimestamp":1786085123,"startTime":"0","endTime":"0","summary":"证券之星8月7日盘中消息，14点35分泓博医药（301230）触及涨停板。其所属行业医疗服务目前上涨。领涨股为博腾股份。该股为基因编辑，减肥药，创新药概念热股，当日基因编辑概念上涨7.16%，减肥药概念上涨6.46%，创新药概念上涨5.99%。8月6日的资金流向数据方面，主力资金净流出931.42万元，占总成交额3.18%，游资资金净流出1174.77万元，占总成交额4.01%，散户资金净流入2106.19万元，占总成交额7.19%。近5日资金流向一览见下表：泓博医药主要指标及行业内排名如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700020409.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327487","title":"泓博医药(301230)7月31日股东户数2.44万户，较上期减少7.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327487","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327487?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:45","pubTimestamp":1785750328,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泓博医药披露，截至2026年7月31日公司股东户数为2.44万户，较7月20日减少2065.0户，减幅为7.79%。在医疗服务行业个股中，泓博医药股东户数低于行业平均水平，截至7月31日，医疗服务行业平均股东户数为4.92万户。从股价来看，2026年7月20日至2026年7月31日，泓博医药区间跌幅为12.43%，在此期间股东户数减少2065.0户，减幅为7.79%。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300024131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656293033","title":"泓博医药：截至2026年7月31日股东户数为24,436户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656293033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656293033?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:37","pubTimestamp":1785742674,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)08月03日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司最新股东人数是多少泓博医药回复：尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年7月31日（交易日），公司的股东户数为24,436户。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014973.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656329536","title":"泓博医药：2025年度海外业务销售收入占主营业务收入的69.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656329536","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656329536?lang=zh_cn&edition=full","pubTime":"2026-08-03 15:37","pubTimestamp":1785742669,"startTime":"0","endTime":"0","summary":"投资者提问：公司2025年海外收入占比69.22%，请具体披露：2026年上半年海外收入占比变化及主要区域分布；美国《生物安全法案》温和落地后，北美Top 20药企中与公司有CDMO/CRO合作的客户数量及订单金额区间；欧洲/日本市场拓展进度。2025年度，公司海外业务销售收入占主营业务收入的69.22%，业务覆盖美国、印度及欧洲部分国家和地区。2026年上半年具体经营数据及客户、订单情况属于商业敏感及未公开经营信息。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300014959.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870917","title":"泓博医药：临床Ⅰ期7个、临床Ⅱ期1个","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870917","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655870917?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415952,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的领导您好，公司提及CADD/AIDD平台已累计服务104个新药项目、8个进入临床、53家客户 ——其中是否有项目进入临床II期或III期？截至2025年底，公司CADD/AIDD平台已累计为104个新药项目提供技术支持，其中8个项目进入临床实验阶段，具体为：临床Ⅰ期7个、临床Ⅱ期1个。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037425.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655870912","title":"泓博医药：CADD/AIDD技术平台已累计为104个新药项目提供技术支持","url":"https://stock-news.laohu8.com/highlight/detail?id=2655870912","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655870912?lang=zh_cn&edition=full","pubTime":"2026-07-30 20:52","pubTimestamp":1785415952,"startTime":"0","endTime":"0","summary":"投资者提问：董秘你好，2025年全年及2026年一季度，CADD/AIDD技术平台赋能的项目中，有多少形成了实际的合同订单？截至2025年12月底，公司CADD/AIDD技术平台已累计为104个新药项目提供技术支持，其中8个项目已进入临床实验阶段。平台服务客户总数达53家，涵盖国内外多家创新药企与生物技术公司。公司的CADD/AIDD平台是赋能公司早期药物研发的核心技术手段，已深度融入公司现有的研发服务体系中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000037426.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655822295","title":"7月30日泓博医药跌6.47%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2655822295","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655822295?lang=zh_cn&edition=full","pubTime":"2026-07-30 16:59","pubTimestamp":1785401945,"startTime":"0","endTime":"0","summary":"证券之星消息，7月30日泓博医药跌6.47%创60日新低，收盘报22.55元，换手率6.2%，成交量10.1万手，成交额2.35亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000026392.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655826047","title":"泓博医药：关于减肥药（含GLP-1相关）领域，公司具备丰富的技术服务能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2655826047","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655826047?lang=zh_cn&edition=full","pubTime":"2026-07-30 15:30","pubTimestamp":1785396624,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)07月30日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的领导您好。市场高度关注减肥药产业链，公司是否考虑发布专项自愿性信息披露公告，向市场详细介绍在GLP-1等热门赛道的技术储备与订单进展？泓博医药回复：尊敬的投资者，您好！关于减肥药（含GLP-1相关）领域，公司具备丰富的技术服务能力，已为多个客户提供新药研发技术服务，相关业务进展均按正常商业节奏推进。由于公司与合作客户均签署了保密协议，需严格履行保密义务，无法透露具体的项目信息。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026073000018991.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653236700","title":"7月24日泓博医药跌5.47%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653236700","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653236700?lang=zh_cn&edition=full","pubTime":"2026-07-24 16:54","pubTimestamp":1784883273,"startTime":"0","endTime":"0","summary":"证券之星消息，7月24日泓博医药跌5.47%，收盘报24.7元，换手率5.91%，成交量9.62万手，成交额2.43亿元。重仓泓博医药的公募基金请见下表：根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共1家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400029030.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653672224","title":"股市必读：泓博医药（301230）7月23日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2653672224","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653672224?lang=zh_cn&edition=full","pubTime":"2026-07-24 01:18","pubTimestamp":1784827095,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘，泓博医药报收于26.13元，下跌1.4%，换手率6.64%，成交量10.81万手，成交额2.84亿元。董秘最新回复投资者： 尊敬的董秘你好，请问公司有没有为武田提供该药物CRO/CDMO研发生产服务?目前公司无相关的合作与自研管线。交易信息汇总资金流向7月23日主力资金净流出738.81万元；游资资金净流入1578.41万元；散户资金净流出839.6万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400001027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301230"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653717451","title":"泓博医药：目前公司无相关的合作与自研管线","url":"https://stock-news.laohu8.com/highlight/detail?id=2653717451","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653717451?lang=zh_cn&edition=full","pubTime":"2026-07-23 16:03","pubTimestamp":1784793790,"startTime":"0","endTime":"0","summary":"证券之星消息，泓博医药(301230)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：尊敬的董秘你好，请问公司有没有为武田提供该药物CRO/CDMO研发生产服务?公司有没有OX2R激动剂制药自研管线?泓博医药回复：尊敬的投资者您好！目前公司无相关的合作与自研管线。感谢关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300029774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652095104","title":"7月17日泓博医药跌16.34%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652095104","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652095104?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:00","pubTimestamp":1784278809,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日泓博医药跌16.34%，收盘报28.72元，换手率19.93%，成交量25.03万手，成交额7.61亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455881","title":"7月15日泓博医药涨5.06%，长城消费增值混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455881","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651455881?lang=zh_cn&edition=full","pubTime":"2026-07-15 16:37","pubTimestamp":1784104652,"startTime":"0","endTime":"0","summary":"证券之星消息，7月15日泓博医药涨5.06%，收盘报42.15元，换手率17.08%，成交量21.45万手，成交额9.1亿元。重仓泓博医药的公募基金请见下表：根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共5家，其中持有数量最多的公募基金为长城基金的长城消费增值混合A。长城消费增值混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500031244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651663701","title":"股市必读：泓博医药（301230）7月10日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651663701","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651663701?lang=zh_cn&edition=full","pubTime":"2026-07-13 02:10","pubTimestamp":1783879821,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，泓博医药报收于40.16元，上涨13.13%，换手率14.53%，成交量18.24万手，成交额7.1亿元。董秘最新回复投资者： 你好，请问截至6月30日股东人数，谢谢董秘： 尊敬的投资者您好！根据中登公司下发的股东名册，截至2026年6月30日（交易日），公司的股东户数为21,845户。交易信息汇总资金流向7月10日主力资金净流入383.7万元，占总成交额0.0%；游资资金净流出4617.27万元，占总成交额0.0%；散户资金净流入4233.57万元，占总成交额0.0%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300001093.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301230","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787860852769,"stockEarnings":[{"period":"1week","weight":-0.1263},{"period":"1month","weight":0.3362},{"period":"3month","weight":0.2084},{"period":"6month","weight":-0.042},{"period":"1year","weight":0.1307},{"period":"ytd","weight":0.4327}],"compareEarnings":[{"period":"1week","weight":0.0135},{"period":"1month","weight":0.0376},{"period":"3month","weight":-0.0275},{"period":"6month","weight":-0.0496},{"period":"1year","weight":0.0411},{"period":"ytd","weight":-0.0031}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海泓博智源医药股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"29532人(较上一季度增加20.85%)","perCapita":"5510股","listingDate":"2022-11-01","address":"上海市浦东新区庆达路315号23幢","registeredCapital":"18094万元","survey":"　　上海泓博智源医药股份有限公司的主营业务是药物发现、制药工艺的研究开发以及原料药中间体的商业化生产。公司的主要产品是药物发现（CRO）、工艺研究与开发（CRO/CDMO）、商业化生产（含CMO）。","listedPrice":40},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泓博医药,301230,泓博医药股票,泓博医药股票老虎,泓博医药股票老虎国际,泓博医药行情,泓博医药股票行情,泓博医药股价,泓博医药股市,泓博医药股票价格,泓博医药股票交易,泓博医药股票购买,泓博医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泓博医药(301230)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泓博医药(301230)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}